Efficacy and safety of telbivudine to prevent mother‐to‐child transmission of hepatitis B virus in middle‐ and late‐stage pregnancy with high viral loads

Objective To observe the efficacy and safety of telbivudine on mother‐infant blockade in pregnant women with hepatitis B virus (HBV) DNA. Methods A total of 141 pregnant women between 24 and 28 weeks of gestation and chronic HBV carriers with HBV DNA ≥106 copies/mL were enrolled, 105 in the treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2019-12, Vol.91 (12), p.2153-2157
Main Authors: Xu, Jing, Tao, Lin lin, Ma, Li xian
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
Deoxyribonucleic acid
DNA
drug efficacy
fetus safety
Gestation
Hepatitis
Hepatitis B
Hepatitis B surface antigen
hepatitis B virus
Infants
Injection
Interferon
mother‐to‐infant transmission
Pregnancy
Safety
Security
telbivudine
Vaccines
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To observe the efficacy and safety of telbivudine on mother‐infant blockade in pregnant women with hepatitis B virus (HBV) DNA. Methods A total of 141 pregnant women between 24 and 28 weeks of gestation and chronic HBV carriers with HBV DNA ≥106 copies/mL were enrolled, 105 in the treatment group and 36 in the control group. The treatment group was given telbivudine 600 mg/d oral, and the control group did not use antiviral drugs. Hepatitis B immunoglobulin 200 IU intramuscular injection and hepatitis B vaccine (HBVac) 10 μg subcutaneous injection were given to the infants in both groups within 12 hours after birth, and 10 μg of HBVac was subcutaneously injected when the infants were 1‐month and 6‐month old. Safety endpoints including HBV DNA quantification, liver function, CK were observed before treatment, 4 weeks after treatment, before delivery, and 24 weeks after delivery. Results There was no difference in HBV DNA levels between the two groups before treatment and 6 months after delivery (P > .05). The HBV DNA level in the treatment group was significantly lower than that in the control group before delivery (P 
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.25566